About Akorn
Akorn is a company based in Lake (United States) founded in 1948 was acquired by Biological E in August 2020. It operates as a Reseller / Distribution. The company has 1,367 employees as of December 31, 2022. Akorn has completed 3 acquisitions, including Hi-Tech, Thera Tears and VersaPharm. Akorn offers products and services including Buprenorphine, Naloxone, Phenylephrine, Albuterol Sulfate Inhalation Solution, and Anased (Xylazine) Injection.
- Headquarter Lake, United States
- Employees 1367 as on 31 Dec, 2022
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Akorn Operating Company Llc
-
Annual Revenue
$682.43 M (USD)-2as on Dec 31, 2019
-
Net Profit
-$226.77 M (USD)44as on Dec 31, 2019
-
EBITDA
-$188.06 M (USD)52as on Dec 31, 2019
-
Latest Funding Round
$120 M (USD), Post-IPO
May 26, 2011
-
Investors
Biological E
& 1 more
-
Employee Count
1367
as on Dec 31, 2022
-
Investments & Acquisitions
Hi-Tech
& 2 more
- Acquired by
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Akorn
Akorn offers a comprehensive portfolio of products and services, including Buprenorphine, Naloxone, Phenylephrine, Albuterol Sulfate Inhalation Solution, and Anased (Xylazine) Injection.
Buprenorphine is provided for opioid dependency treatment solutions.
Naloxone is offered for reversing opioid overdose effects.
Phenylephrine is supplied for nasal congestion relief purposes.
Albuterol is delivered for asthma and respiratory conditions.
Xylazine is used for sedation in veterinary applications.
People of Akorn
Unlock access to complete
Software Development Team
17 people
Product Management Team
7 people
Leadership Team
7 people
Senior Team
7 people
Sales and Marketing
6 people
Legal and Compliance
5 people
Human Resources and Administration
4 people
Manager Team
3 people
Unlock access to complete
Funding Insights of Akorn
Investors in Akorn
Akorn has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Biological E and Fresenius Kabi.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Vaccines and therapeutics for multiple diseases are developed and marketed.
|
Locked | Locked | Locked | |
|
Healthcare solutions in pharmaceuticals, nutrition, MedTech, and biopharmaceuticals.
|
Locked | Locked | Locked |
Investor details for Akorn
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Akorn
Akorn has strategically engaged in corporate development activities, having acquired 3 companies. Notable acquisitions include Hi-Tech, Thera Tears and VersaPharm.
Investment portfolio details for Akorn
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Eye drops are manufactured by Thera Tears for therapeutic purposes.
|
Locked | Locked | 1997 | Locked | |
|
Generic pharmaceuticals are developed and marketed in key categories.
|
Locked | Locked | 1995 | Locked | |
|
Generic, branded, and OTC pharmaceutical products are manufactured.
|
Locked | Locked | 1983 | Locked |
Complete acquisition details for Akorn
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Akorn
Detailed financials for Akorn
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Akorn Comparisons
Peer comparison for Akorn
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Akorn
Detailed competitors of Akorn
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Akorn
Complete news archive for Akorn
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Akorn
Akorn was founded in 1948 and raised its 1st funding round 63 years after it was founded.
Akorn is headquartered in Lake, United States.
As of Dec 31, 2022, the latest employee count at Akorn is 1,367.
Annual revenue of Akorn is $682.43M as on Dec 31, 2019.
Akorn Operating Company LLC was engaged in the distribution of pharmaceutical products, including generics and veterinary solutions. Operations covered a range of medications such as Buprenorphine, Naloxone, and Albuterol Sulfate Inhalation Solution. The company served the healthcare sector with a focus on human and animal health. In February 2023, it filed for Chapter 7 bankruptcy and ceased all operations.
Akorn offers Buprenorphine, Naloxone, Phenylephrine, Albuterol Sulfate Inhalation Solution, and Anased (Xylazine) Injection.
Akorn has made 3 acquisitions, including Hi-Tech, Thera Tears, and VersaPharm.
Akorn has 2 investors. Key investors include Biological E, and Fresenius Kabi.